Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Glycemic Responses
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this project is to determine the impact of incorporating brewers' spent grain into cookie formulations on postprandial blood glucose absorption levels following consumption. The methodology for assessing blood glucose response to cookies formulated with brewers' spent grain is described as follows. A total of 20 participants will be recruited from the Universidad Católica del Uruguay. Volunteers will be recruited through institutional email dissemination, with Dr. María Belén Gutiérrez serving as the research contact. Eligible participants will be healthy adults without diagnosed diseases and not taking regular medication. Inclusion criteria will be: men and women aged 18 to 75 years and a body mass index (BMI) between 18.5 and 30 kg/m². Exclusion criteria will include: pregnancy, diabetes, special dietary regimens, recent surgeries, and hypersensitivity or allergy to any of the components of the tested foods. A physical assessment will be performed for each participant, including waist and hip circumferences, body weight, and height. Each participant will be assigned a volunteer identification code, and the data analyst will be blinded to the identity of the participants. Volunteers may withdraw from the study at any time without any consequences. Participants will be studied on four separate occasions (one session per week). On two occasions they will receive 30 g of a commercial María cookie, and on the other two occasions 30 g of a reduced-sugar cookie containing 17% extruded brewers' spent grain. During the study period, participants will be asked to maintain their usual lifestyle. Participants will attend the University Clinic in the morning after an 8-10 hour overnight fast. After a fasting blood sample is obtained, the corresponding treatment will be provided, and participants will have 15 minutes to consume it. Capillary blood samples will be collected at 15, 30, 45, 60, 90, and 120 minutes after the start of treatment consumption. Blood sampling will be performed via capillary puncture using a commercially available glucometer, with disposable lancets used for each measurement and safely discarded after each sample. Sample collection will be carried out by trained personnel from the Department of Health and Well-being of the Universidad Católica del Uruguay. During the testing period, participants will be allowed to drink up to 250 mL of water and must remain seated. For each participant and each treatment day, a data collection sheet will be used to record all measurements. After each experimental session, participants will receive a breakfast voucher.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Other: Food Intervention — The participant eats 30g of assigned biscuit

Primary Outcomes

  • Postrpandial Blood Glucose (From baseline to 120 minutes post-consumption)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2026-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad Católica del Uruguay
Contact Information
Study Contact:
Maria Belen Gutierrez, PhD
+59898961870
belen.gutierrez@ucu.edu.uy
Sonia Cozzano, PhD
+98141561
scozzano@ucu.edu.uy
Maria Belen Gutierrez, PhD
+59898961870
belen.gutierrez@ucu.edu.uy
Universidad Católica del Uruguay
Interventions
  • Other: Food Intervention — The participant eats 30g of assigned biscuit
Study Locations (1 sites)
Universidad Católica del Uruguay, Montevideo, 11600 Uruguay
Eligibility Criteria
Inclusion Criteria: * Body mass index (BMI) between 18.5 and 30 kg/m². Exclusion Criteria: * Pregnancy * Diabetes * Recent surgerys * Food allergies
Conditions Diabetes Mellitus, Diabetes Mellitus Typ...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes self-management education is essential for achieving optimal glycemic control, but conventional education does not meet the needs of all patients. SugarVita 2.0 is a serious digital game designed to improve diabetes self-management through interactive gameplay and a semi-personalized glucose simulator. This multicenter, single-arm, 12-week pilot study will evaluate the usability of SugarVita 2.0 and its effects on diabetes self-management, self-confidence, diabetes-related distress, diabetes knowledge, HbA1c, and user engagement in adults with type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: SugarVita 2.0 — SugarVita 2.0 is a serious digital educational game designed to improve diabetes self-management. Players make decisions regarding nutrition, physical activity and diabetes medication while receiving direct visual feedback through a semi-personalized glucose simulator. The game is intended to increase diabetes-related knowledge, self-management skills and self-confidence through interactive learning and repeated gameplay

Primary Outcomes

  • Change in diabetes self-confidence measured using the Confidence in Diabetes Self-Care Scale (VDZ) (Baseline and Week 12)
  • Change in diabetes self-management measured using the Diabetes Management Self-Efficacy Scale (DMSES) (Baseline and Week 12)
  • Change in diabetes-related distress measured using the Problem Areas in Diabetes (PAID) scale (Baseline and Week 12)
  • Change in diabetes-related knowledge measured using the Michigan Diabetes Knowledge Test (DKT) (Baseline and Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-05
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maxima Medical Center
Principal Investigators:
  • Pleun Wouters - van Poppel, MSc (PRINCIPAL_INVESTIGATOR) - Maxima Medical Center
Contact Information
Study Contact:
Dr. Pleun Wouters-van Poppel, PhD
+31 (0)40 888 6300
pleun.van.poppel@mmc.nl
Edouard Reinders, MSc
+31 (0)40 888 6300
edouard.reinders@mmc.nl
Dr. Pleun Wouters- van Poppel, MSc
+31 (0)40 888 6300
pleun.van.poppel@mmc.nl
Maxima Medical Centre
Interventions
  • Behavioral: SugarVita 2.0 — SugarVita 2.0 is a serious digital educational game designed to improve diabetes self-management. Players make decisions regarding nutrition, physical activity and diabetes medication while receiving direct visual feedback through a semi-personalized glucose simulator. The game is intended to increase diabetes-related knowledge, self-management skills and self-confidence through interactive learning and repeated gameplay
Study Locations (1 sites)
Maxima Medical Centre, Eindhoven, North Brabant 5631 BM Netherlands
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of type 2 diabetes mellitus (T2DM) * Written informed consent obtained before any study procedures * HbA1c \>55 mmol/mol prior to study participation * For participants with T2DM only: BMI \>25 kg/m² * Sufficient command of the Dutch language to complete study questionnaires Exclusion Criteria: * Pregnancy or breastfeeding * Active malignancy, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin
Conditions Obesity, Weight Reduction, Cardiometabol...
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes mellitus. The study will be conducted at the Asian Institute of Medical Sciences (AIMS), Hyderabad, Sindh, Pakistan. A total of 60 obese adults aged 18 years or older with a body mass index (BMI) of 27.5 kg/m² or greater according to World Health Organization Asian cutoffs and without type 2 diabetes mellitus (fasting blood glucose \<126 mg/dL and HbA1c \<6.5%) will be enrolled. Eligible participants will receive once-weekly subcutaneous semaglutide following a standard dose titration schedule of 0.25 mg weekly for four weeks, 0.5 mg weekly for four weeks, and 1.0 mg weekly for the remaining 16 weeks, for a total treatment duration of 24 weeks. All participants will receive standardized lifestyle counseling, including a hypocaloric diet with a 500-750 kcal/day deficit and at least 150 minutes per week of moderate-intensity physical activity. The primary outcome is the percentage change in body weight from baseline to 24 weeks. Secondary outcomes include changes in body mass index, waist circumference, systolic and diastolic blood pressure, lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides), liver enzymes (alanine aminotransferase and aspartate aminotransferase), and quality of life. Safety will be assessed through continuous monitoring of adverse events and adverse drug reactions with causality assessment using the Naranjo Adverse Drug Reaction Probability Scale. Clinical and laboratory assessments will be conducted at baseline, 12 weeks, and 24 weeks. Data will be analyzed using descriptive and inferential statistics, including paired t-tests or non-parametric equivalents and repeated measures analysis, with a significance level of p \< 0.05. The study will be conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, with approval from the AIMS Institutional Review Board and written informed consent obtained from all participants. The trial aims to generate locally relevant clinical evidence on the effectiveness and safety of low-dose semaglutide for obesity management in non-diabetic Pakistani adults.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg) — Once-weekly subcutaneous injections following a titration schedule (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for remaining 16 weeks) for a total of 24 weeks.

Primary Outcomes

  • Percentage Change in Body Weight (Baseline to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-08-01
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Asian Institute Of Medical Sciences
Principal Investigators:
  • Dr. Fatima Nadeem (STUDY_DIRECTOR) - Asian Institute Of Medical Sciences
  • Sadik Memon (PRINCIPAL_INVESTIGATOR) - Asian Institute Of Medical Sciences
Contact Information
Study Contact:
Fatima Nadeem Dr, Pharm-D, Mphil
+923080744996
fatima.nadeem2401@gmail.com
Sadik Memon Dr
+923009373868
sadikmemon@gmail.com
Asian Institute of Medical Sciences
Haris Rathore
+923138189653
aimshyd786@gmail.com
Asian Institute of Medical Sciences
Interventions
  • Drug: Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg) — Once-weekly subcutaneous injections following a titration schedule (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for remaining 16 weeks) for a total of 24 weeks.
Study Locations (1 sites)
Asian Institute of Medical Sciences, Hyderābād, Sindh 71000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older. * Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs. * No diagnosis of type 2 diabetes mellitus, confirmed by: Fasting blood glucose \< 126 mg/dL, and HbA1c \< 6.5% within three months prior to enrollment. * Willingness and ability to provide written informed consent. * Willingness to comply with study procedures, including weekly injections and lifestyle counseling. Exclusion Criteria: * History of pancreatitis. * History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). * Pregnant or lactating women. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or hepatic impairment (ALT or AST \> 3× upper limit of normal). * Current use of other anti-obesity medications. * Known hypersensitivity to semaglutide or any component of the formulation. * Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.
Conditions Chronic Kidney Disease(CKD), Type 2 DM, ...
Phase NA
Enrollment 212
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: (IRIS-CKD Management Program): Education — Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.
  • Other: (IRIS-CKD Management Program): GDMT — Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.

Primary Outcomes

  • CKD GDMT Opportunity Score at 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-28
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 212 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: Bayer, Boehringer Ingelheim
Principal Investigators:
  • Neha Pagidipati, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Gretchen Sanders, MSN
919 6687829
gretchen.sanders@duke.edu
lisa monk, MSN
lisa.monk@duke.edu
Sarah Machado
205-934-7649
smachado@uabmc.edu
University of Alabama
Interventions
  • Other: (IRIS-CKD Management Program): Education — Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.
  • Other: (IRIS-CKD Management Program): GDMT — Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.
Study Locations (7 sites)
University of Alabama, Birmingham, Alabama 35233 United States
Orlando Health, St. Petersburg, Florida 33701 United States
University of Michigan, Ann Arbor, Michigan 48109 United States
Essentia Institute of Rural Health, Duluth, Minnesota 55805 United States
Duke University, Durham, North Carolina 27707 United States
Houston Methodist, Houston, Texas 77030 United States
Baylor Scott & White, Temple, Texas 76508 United States
Eligibility Criteria
Inclusion Criteria: * (CKD Management) * Adults with type 2 diabetes (T2D) * Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP) * Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment): * UACR \>300 mg/g or * eGFR \<45 ml/min/1.73 m2 or * UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2 * Receiving \<100% GDMT at baseline. For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.). Exclusion Criteria: * (CKD Management) * Type 1 diabetes * Most recent eGFR \<20 ml/min/1.73 m2 * Prior kidney transplant * Autosomal dominant polycystic kidney disease (ADPKD) * Active pregnancy or plans for conception within 1 year
Conditions Type 2 Diabetes
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to assess the potential benefits of integrating a video covering topics related to nutrition education, food literacy and type 2 diabetes into Seva Food Banks current programs (Culinary Training for Youth, Culinary Training for Newcomers, Cooking Classes for Seniors), to learn if integrating this video can reduce risk of type 2 diabetes by improving diet quality, nutrition knowledge, attitudes, and behaviors among participants of the programs. The main question it aims to answer is: How does the integration of a nutrition education video covering topics related to food literacy and type 2 diabetes within Seva Food Bank's Culinary Training programs for youth, newcomers, and seniors influence participants' diet quality, nutrition knowledge, attitudes, and behaviors? Participants will: * Complete a baseline questionnaire before watching the educational video * Watch the nutrition education video * Complete a questionnaire at 2-weeks and again 1-month post-intervention to assess sustained effects and maintenance.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Educational Video — Participants will be invited to watch an educational video that was co-developed by past participants of Seva Food Bank's programs and a working group comprised of people with lived experiences (those living with type 2 diabetes and those at risk), culinary instructors, dietary experts/clinicians, and community organization partners. This video will be approximately 5-minutes long and covers nutrition topics related to Canada's Food Guide and type 2 diabetes.

Primary Outcomes

  • Changes in diet quality (baseline and 1-2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-09
Completion: 2026-12
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Toronto
Contact Information
Study Contact:
Vasanti Malik, MSc, ScD
4169785556
vasanti.malik@utoronto.ca
Selina Quibrantar, MSc
4169785556
selina.quibrantar@utoronto.ca
Manreet Lachhar
905-361-7382
coordinator@sevafoodbank.com
Seva Food Bank
Interventions
  • Behavioral: Educational Video — Participants will be invited to watch an educational video that was co-developed by past participants of Seva Food Bank's programs and a working group comprised of people with lived experiences (those living with type 2 diabetes and those at risk), culinary instructors, dietary experts/clinicians, and community organization partners. This video will be approximately 5-minutes long and covers nutrition topics related to Canada's Food Guide and type 2 diabetes.
Study Locations (1 sites)
Seva Food Bank, Mississauga, Ontario L4T 1G3 Canada
Eligibility Criteria
Inclusion Criteria: * Individuals who are currently participating in either the Culinary Training for Youth, Culinary Training for Newcomers, or Cooking Classes for Seniors programs at Seva Food Bank * Must be 16 years of age or older * Residents of the Peel region, in Ontario, Canada Exclusion Criteria: * Individuals who are not currently participants in either the Culinary Training for Youth, Culinary Training for Newcomers, Cooking Classes for Seniors programs at Seva Food Bank * Under the age of 16 * Not a resident of the Peel region, in Ontario, Canada
Conditions Type 2 Diabetes
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

It is now well documented that changes in gut microbiota composition accompany obesity and type 2 diabetes (T2D) and contribute to low-grade inflammation, insulin resistance,and glucose intolerance. It is not yet clear if T2D predisposes the intestine to allow more microbial products or possibly live bacteria to subvert the gut mucosal barrier. However, it is known that hyperglycemia during T2D induces a more permissive gut barrier allowing increased penetration of microbes and their products into the blood. An important next step is to determine which strains of bacteria promote dysbiosis, allowing bacteria or bacterial components to subvert the gut barrier and alter glucose control. It is hypothesized that gut microbes in the colon and other lower gut segments are key modulators of energy balance, glucose homeostasis and insulin sensitivity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopy and duodenal biopsy and sampling — All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples

Primary Outcomes

  • Microbial signature (One week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-02-01
Completion: 2025-12-01
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laval University
Principal Investigators:
  • André Marette, PhD (PRINCIPAL_INVESTIGATOR) - Laval University
Contact Information
Study Contact:
Geneviève Pilon, PhD
418-656-8711
Genevieve.Pilon@criucpq.ulaval.ca
André Tremblay, Ph.D
1-418-656-2131
andre.tremblay@fsaa.ulaval.ca
INAF, Université Laval
Interventions
  • Procedure: Endoscopy and duodenal biopsy and sampling — All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
Study Locations (1 sites)
INAF, Université Laval, Québec, Quebec G1V 0A6 Canada
Eligibility Criteria
Inclusion Criteria: * T2DB de novo or non T2DB patients Exclusion Criteria: * oral hypoglycemic agents or lipidlowering or antihypertensive drugs
Conditions Diabetes Mellitus, Type 2
Phase PHASE2
Enrollment 94
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Active comparator Taurine — Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
  • Other: Placebo Comparator — Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle

Primary Outcomes

  • HbA1c (baseline and 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-06-12
Completion: 2026-12-01
Eligibility
Age: 30 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital de Clinicas de Porto Alegre
Principal Investigators:
  • Beatriz D Schaan, PhD (PRINCIPAL_INVESTIGATOR) - Hospital de Clinicas de Porto Alegre
Contact Information
Study Contact:
Beatriz D Schaan, PhD
55 51 3359-8000
bschaan@hcpa.edu.br
Rosane Gomez, PhD
55 51 33082823
rogomez@hcpa.edu.br
Beatriz D'agord Schaan, PhD
55+513359-8000
bschaan@hcpa.edu.br
Hospital de Clínicas
Interventions
  • Drug: Active comparator Taurine — Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
  • Other: Placebo Comparator — Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
Study Locations (1 sites)
Hospital de Clínicas, Porto Alegre, Rio Grande do Sul 90630090 Brazil
Eligibility Criteria
Inclusion criteria * Female and male individuals, with clinical diagnosis of DM2 for at least 6 months; * Age over 30 years; * BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months; * HbA1c between 7.5% and 10.5%. Exclusion criteria * Use of herbal supplements, antioxidants, and multivitamins in the last 3 months; * Pregnancy or lactation; * Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h; * Myocardial infarction in the last than 6 months * Current neoplasia; * Chronic use of glucocorticoids; * Bariatric surgery.
Conditions Asthma (Diagnosis)
Phase NA
Enrollment 430
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study pilots REACH, Resources and Education for Addressing Chronic Health, a service model to facilitate care coordination and communication across medical, school, and home settings. REACH seeks to address barriers to school-based asthma management, improving health and educational outcomes and reducing negative impacts for children with asthma.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: REACH — The REACH intervention which includes (a) a strategic communication or messaging and dissemination strategy to build school and family relationships and trust, (b) capacity building activities to improve asthma knowledge and awareness through asthma education and resource provided both digitally and in-person, and (c) a tool or dashboard that allows records and communication sharing across healthcare and educational systems to facilitate care coordination (REACH tool).

Primary Outcomes

  • Asthma knowledge and awareness (Measured at baseline and at study completion (average of 1 year))
  • Implementation (Measured at trial mid-point (approximately 6 months following enrollment) for school nurses only, and at study completion (average of 1 year) for all noted groups)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-09
Completion: 2030-06
Eligibility
Age: 3 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 430 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Contact Information
Study Contact:
Dr. Kelly M. Harris, PhD, CCC-SLP
314-273-3242
kmharris@wustl.edu
Madelyn Yoo, MSOT
314-400-8118
m.g.yoo@wustl.edu
Madelyn Yoo, MSOT
314-400-8118
m.g.yoo@wustl.edu
WashU School of Medicine
Interventions
  • Other: REACH — The REACH intervention which includes (a) a strategic communication or messaging and dissemination strategy to build school and family relationships and trust, (b) capacity building activities to improve asthma knowledge and awareness through asthma education and resource provided both digitally and in-person, and (c) a tool or dashboard that allows records and communication sharing across healthcare and educational systems to facilitate care coordination (REACH tool).
Study Locations (1 sites)
WashU School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Parents (N=200)/Children (N=200) Inclusion criteria for recruited parents/children: * parents/caregivers with at least one child with asthma or present to the nurse with asthma symptoms in the partner school district, * child with asthma must have a diagnosis of asthma or suspected asthma due to asthma symptom-related healthcare utilization and/or multiple visits to the school nurse (\>1) * attend a school in one of the partner school districts * have access to email and a computer or other mobile device * receive care within the BJH/ WUSM system (an indicator of participation in the electronic health record system). Exclusion Criteria for recruited families: * Child does not have asthma and do not present to school nurse with asthma symptoms * Child does not attend one of the identified schools in a partner school district * Children in foster care or wards of the state School Nurses (Implementers) (N=15) Inclusion Criteria for school nurses: * Employed by partner school district and work in an identified building * Provide care to students with asthma or present with asthma symptoms Exclusion Criteria for school nurses: \- Do not work for partner school district or for an identified building Providers (N =15) Inclusion Criteria for Providers: \- Provide care to a child participant on the study Exclusion Criteria for Providers: \- Do not provide care to a child participant on the study
Conditions Asthma Childhood
Phase NA
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate whether incorporating FeNO monitoring into routine pediatric asthma care improves clinical outcomes relative to a historical cohort managed without FeNO

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: FENO — Registration: Eligible participants will be registered consecutively during clinic visits after obtaining informed consent (and assent where applicable). * Randomization: As this is an observational study comparing prospective data with historical controls, no randomization will be performed. 2.4 Data Gathering Methods * Prospective FeNO Group: Monthly data collection over 3 months including ACT/ C-ACT questionnaires, FeNO measurements using portable point-of-care devices, spirometry (FEV1%), and peripheral blood eosinophil counts. * Historical Control Group: Extraction of relevant clinical data (ACT/C-ACT scores, spirometry, eosinophil counts, ICS adherence, and exacerbation records) from electronic medical records covering a comparable 3-month timeframe. 2.5 Procedures and Central Laboratories * FeNO measurements will be conducted using a validated, portable FeNO device standardized across study sites. * Spirometry will be performed according to American Thoracic Society guidelines
  • Diagnostic Test: PFT — Registration: Eligible participants will be registered consecutively during clinic visits after obtaining informed consent (and assent where applicable). * Randomization: As this is an observational study comparing prospective data with historical controls, no randomization will be performed. 2.4 Data Gathering Methods * Prospective FeNO Group: Monthly data collection over 3 months including ACT/ C-ACT questionnaires, FeNO measurements using portable point-of-care devices, spirometry (FEV1%), and peripheral blood eosinophil counts. * Historical Control Group: Extraction of relevant clinical data (ACT/C-ACT scores, spirometry, eosinophil counts, ICS adherence, and exacerbation records) from electronic medical records covering a comparable 3-month timeframe. 2.5 Procedures and Central Laboratories * FeNO measurements will be conducted using a validated, portable FeNO device standardized across study sites. * Spirometry will be performed according to American Thoracic Society guidelines

Primary Outcomes

  • correlations (6 MONTH)
  • Establish correlations between FeNO levels and established asthma control markers such as ACT scores, eosinophils, and FEV1%. (12 MONTH)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-12
Completion: 2026-11-12
Eligibility
Age: 6 Years – 14 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King Faisal Specialist Hospital & Research Center
Principal Investigators:
  • Nariman Alrabie (PRINCIPAL_INVESTIGATOR) - king Faisal specialized hospital and research center
Contact Information
Study Contact:
Abrar Barnawi
966551266326
abarnawi1@kfshrc.edu.sa
Bader Alshrabi
966561681079
balshrabi@kfshrc.edu.sa
Abrar Barnawi
966551266326
abarnawi1@kfshrc.edu.sa
king Faisal specialized hospital and research center
Interventions
  • Diagnostic Test: FENO — Registration: Eligible participants will be registered consecutively during clinic visits after obtaining informed consent (and assent where applicable). * Randomization: As this is an observational study comparing prospective data with historical controls, no randomization will be performed. 2.4 Data Gathering Methods * Prospective FeNO Group: Monthly data collection over 3 months including ACT/ C-ACT questionnaires, FeNO measurements using portable point-of-care devices, spirometry (FEV1%), and peripheral blood eosinophil counts. * Historical Control Group: Extraction of relevant clinical data (ACT/C-ACT scores, spirometry, eosinophil counts, ICS adherence, and exacerbation records) from electronic medical records covering a comparable 3-month timeframe. 2.5 Procedures and Central Laboratories * FeNO measurements will be conducted using a validated, portable FeNO device standardized across study sites. * Spirometry will be performed according to American Thoracic Society guidelines
  • Diagnostic Test: PFT — Registration: Eligible participants will be registered consecutively during clinic visits after obtaining informed consent (and assent where applicable). * Randomization: As this is an observational study comparing prospective data with historical controls, no randomization will be performed. 2.4 Data Gathering Methods * Prospective FeNO Group: Monthly data collection over 3 months including ACT/ C-ACT questionnaires, FeNO measurements using portable point-of-care devices, spirometry (FEV1%), and peripheral blood eosinophil counts. * Historical Control Group: Extraction of relevant clinical data (ACT/C-ACT scores, spirometry, eosinophil counts, ICS adherence, and exacerbation records) from electronic medical records covering a comparable 3-month timeframe. 2.5 Procedures and Central Laboratories * FeNO measurements will be conducted using a validated, portable FeNO device standardized across study sites. * Spirometry will be performed according to American Thoracic Society guidelines
Study Locations (2 sites)
King Faisal Sepiclaized Hospital and Research Center, Jeddah, Mecca Region Saudi Arabia
king Faisal specialized hospital and research center, Jeddah, Western Region 21499 Saudi Arabia
Eligibility Criteria
Inclusion Criteria: * Children aged 6 to 14 years with a physician-diagnosed asthma. * Minimum of three months' follow-up at the pediatric respiratory clinic. * Availability of Asthma Control Test (ACT/C-ACT) scores and clinical data Exclusion Criteria: * Presence of other chronic pulmonary diseases (e.g., cystic fibrosis). * Recent respiratory infections within four weeks prior to enrollment. * Current treatment with biologic agents affecting asthma inflammation.
Conditions Chronic Asthma
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The effects of regular exercise on asthma control has not yet been well demonstrated. The aim of this study is to investigate the impact of submaximal aerobic training on exercise tolerance (VO2max - primary outcome) and a set of secondary outcomes: quality of life, asthma symptoms control, bronchial and systemic inflammatory markers, lung function, bronchial hyperresponsiveness, anxiety and depression and body composition in patients with persistant asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Aerobic exercise training — Arm Description: The aerobic training program will be performed indoor three times a week for 12 weeks, under the direct supervision of a chest physician and a physiotherapist. Each aerobic training session will last 75 minutes and will be divided in 5 min of warm-up, 60 min of aerobic training (including 20 minutes on three different ergometers: bicycle, treadmill and rower/elliptical trainers) and 10 min of cool-down. Training intensity is determined by the maximal aerobic power (MAP) previously measured during an initial cardiopulmonary exercise test. Progressive increase in training load during the first three weeks (3x20 minutes at 50% of MAP), followed by 3x20 min at 60% of MAP from weeks 4 to 6, then 3x20 min at 70% of MAP from week 7 to week 9. Finally trainings from week 10 to week 12 include one session of interval training and two sessions of continuous training.
  • Other: Respiratory physiotherapy — Arm Description: Exercises to improve the way of breathing. The breathing exercise sessions will last 30 minutes and be supervised by a physiotherapist 3 times per week.

Primary Outcomes

  • Vo2max (maximum oxygen consumption) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-09-01
Completion: 2028-09-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Liege
Contact Information
Study Contact:
Stephanie Ziant
+3243668568
sziant@chuliege.be
stephanie ziant
+3243668568
Chu Liege
Florence Schleich
Chu Liege
Interventions
  • Other: Aerobic exercise training — Arm Description: The aerobic training program will be performed indoor three times a week for 12 weeks, under the direct supervision of a chest physician and a physiotherapist. Each aerobic training session will last 75 minutes and will be divided in 5 min of warm-up, 60 min of aerobic training (including 20 minutes on three different ergometers: bicycle, treadmill and rower/elliptical trainers) and 10 min of cool-down. Training intensity is determined by the maximal aerobic power (MAP) previously measured during an initial cardiopulmonary exercise test. Progressive increase in training load during the first three weeks (3x20 minutes at 50% of MAP), followed by 3x20 min at 60% of MAP from weeks 4 to 6, then 3x20 min at 70% of MAP from week 7 to week 9. Finally trainings from week 10 to week 12 include one session of interval training and two sessions of continuous training.
  • Other: Respiratory physiotherapy — Arm Description: Exercises to improve the way of breathing. The breathing exercise sessions will last 30 minutes and be supervised by a physiotherapist 3 times per week.
Study Locations (1 sites)
Chu Liege, Liège, Liege 4000 Belgium
Eligibility Criteria
Inclusion Criteria: * asthmatic patient * aged 18- 65 years * ACQ \> 1.5 * stable background treatment comprising at least one inhaled corticosteroid or an anti-leukotriene Exclusion Criteria: * IMC \> 35 * severe osteoarthritis of the knees and hips * unstable angor * Severe uncontrolled hypertension
Conditions Severe Eosinophilic Asthma
Phase Not Applicable
Enrollment 335
Locations 28 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Biological: benralizumab — 30mg s.c. as per SmPC

Primary Outcomes

  • Number and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-20
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 335 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Biological: benralizumab — 30mg s.c. as per SmPC
Study Locations (28 sites)
Research Site, Salerno, Battipaglia 84031 Italy
Research Site, Padova, Cittadella 35013 Italy
Research Site, Teramo, Giulianova 64021 Italy
Research Site, Treviso, Montebelluna 31044 Italy
Research Site, Varese, Tradate 21049 Italy
Research Site, Bari, 70120 Italy
Research Site, Bergamo, 24127 Italy
Research Site, Bologna, 40138 Italy
Research Site, Bologna, 40139 Italy
Research Site, Brescia, 25123 Italy
Eligibility Criteria
Inclusion Criteria: * Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma. * Benralizumab has been prescribed according to the approved label and local reimbursement criteria * Provision of signed Informed Consent Form (ICF) prior to any study-related activities * Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study). Exclusion Criteria: * Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment * Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial. * Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC). * Pregnant or lactating women. * patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement. * Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice
Conditions Asthma, Self-management, Asthma Control
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is a common medical condition in Ireland. Adult patients tend to have periods when their asthma is stable and periods when it worsens. In order to reduce these periods of worsening asthma, effective ongoing management is required day to day by adults with asthma. Teaching adults how to manage their asthma effectively, plays a huge role in improving their asthma and having a better overall quality of life. This education on managing asthma has many different parts to it. Most adults will discover they have asthma through their general practitioner (GP) and it will be continued to be checked and managed through their GP or general practice nurse (GPN) in their primary care clinic for the duration of their lives. This research study is taking place to find out if a new education programme, will help adults manage their asthma better and improve the symptoms of asthma, reducing its overall impact on day-to-day life. This study is also looking at how easy it is to introduce and for nurses to deliver this study within a GP/ primary care centre. This study is to find out if this education programme works in a real life setting and if it can lead to better control of asthma for adults.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: WASP asthma self-management programme — all participants will received the WASP intervention which includes (asthma education, self-management training and behaviour change strategies)

Primary Outcomes

  • Feasibility of implementation (6 months)
  • Education (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal College of Surgeons, Ireland
Contact Information
Study Contact:
Joanne Walsh, MSc
01-4022300
joannewalsh21@rcsi.com
Joanne Walsh, MSc
01-4022300
joannewalsh21@rcsi.com
Royal College of Surgeons Ireland
Interventions
  • Other: WASP asthma self-management programme — all participants will received the WASP intervention which includes (asthma education, self-management training and behaviour change strategies)
Study Locations (1 sites)
Royal College of Surgeons Ireland, Dublin, D D15 AXV5 Ireland
Eligibility Criteria
Inclusion Criteria: * Adults over 18 years old * Adults who meet one of the following criteria: a physician's diagnosis of asthma; coded as asthma (R96) as per the international classification of primary care (ICPC) or international classification of diseases (ICD) code J45 with associated use of asthma medications for 6 months prior to study enrolment. Exclusion Criteria: * Adults under 18 years old * Adults with no diagnosis of asthma * Adults receiving asthma education in a specialist hospital or community setting * Adults unable to give informed consent * Smoking ≥ 10 Pack Year History